Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220889 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
A Phase 1 study of Safety After Oral Intake, sponsored by MDI Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT07220889: Recruiting Phase 1 study of Safety After Oral Intake, sponsored by MDI Therapeutics.
NCT07220889 is a Phase 1 study of Safety After Oral Intake that is actively recruiting participants, run by MDI Therapeutics. The registered enrollment target is 52 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220889, a Phase 1 study of Safety After Oral Intake, is actively recruiting participants, sponsored by MDI Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if drug MDI2517 is safe and to learn more about its drug effects in healthy participants. Healthy participants will take single or multiple doses of drug and the safety and drug levels will be measured.
Primary Outcome
Evaluate the safety of single and multiple ascending oral doses of MDI-2517 in healthy participants. This outcome will be measured using: the number of participants with adverse events (AEs), with abnormal laboratory tests results (chemistry, hematology, coagulation), abnormal vital signs and changes in electrocardiogram" * The type, incidence, severity, seriousness, and relatedness of adverse events (AEs) * The type, incidence, and severity of laboratory abnormalities and changes (chemistry,
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MDI-2517 800mg
- DRUG MDI-2517 1600mg
- DRUG MDI-2517 2400mg
- DRUG MDI-2517 3600mg
Study Locations (1)
Florida
- 1951 NW 7th Avenue, Suite 180 - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2026-06-04 |
| Phase | Phase 1 |
What NCT07220889 shows while recruiting
NCT07220889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Safety After Oral Intake appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT07220889 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07220889 about?
NCT07220889 is a clinical study titled "Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants". The goal of this clinical trial is to learn if drug MDI2517 is safe and to learn more about its drug effects in healthy participants. Healthy participants will take single or multiple doses of drug and the safety and drug levels will be measured.
What is the current status of trial NCT07220889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-11-04. Estimated completion is 2026-06-04.
What conditions does trial NCT07220889 study?
This clinical trial studies the following conditions: Safety After Oral Intake.
What interventions are being tested in trial NCT07220889?
The interventions under investigation include: Placebo (OTHER), MDI-2517 800mg (DRUG), MDI-2517 1600mg (DRUG), MDI-2517 2400mg (DRUG), MDI-2517 3600mg (DRUG).
Who is sponsoring clinical trial NCT07220889?
This trial is sponsored by MDI Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220889 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety After Oral Intake
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220889's enrollment target sits among peer trials
52 957th of 2000 higher than 1,032 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI